Table of Contents Author Guidelines Submit a Manuscript
Journal of Ophthalmology
Volume 2011, Article ID 439025, 5 pages
http://dx.doi.org/10.1155/2011/439025
Case Report

Management and Clinical Outcome of Penetrating Keratoplasty for Long-Term Corneal Changes in Sympathetic Ophthalmia

Department of Ophthalmology, Tennent Institute of Ophthalmology, 1053 Great Western Road, Glasgow G12 0YN, UK

Received 12 November 2010; Accepted 12 February 2011

Academic Editor: Rupert M. Menapace

Copyright © 2011 Saraswathi Ramamurthi et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. D. S. Chu and C. S. Foster, “Sympathetic ophthalmia,” International Ophthalmology Clinics, vol. 42, no. 3, pp. 179–185, 2002. View at Google Scholar · View at Scopus
  2. P. Henkind and G. N. Wise, “Cataract extraction in a sympathizing eye,” American Journal of Ophthalmology, vol. 77, no. 1, pp. 112–114, 1974. View at Google Scholar · View at Scopus
  3. S. K. Ganesh, P. M. Sundaram, J. Biswas, and K. Babu, “Cataract surgery in sympathetic ophthalmia,” Journal of Cataract and Refractive Surgery, vol. 30, no. 11, pp. 2371–2376, 2004. View at Publisher · View at Google Scholar · View at PubMed
  4. C.-C. Chan, “Relationship between sympathetic ophthalmia, phacoanaphylactic endophthalmitis, and Vogt-Koyanagi-Harada disease,” Ophthalmology, vol. 95, no. 5, pp. 619–624, 1988. View at Google Scholar
  5. F. A. Jakabiec, C. C. Marboe, D. M. Knowles II et al., “Human sympathetic ophthalmia. An analysis of the inflammatory infiltrate by hybridoma-monoclonal antibodies, immunochemistry, and correlative electron microscopy,” Ophthalmology, vol. 90, no. 1, pp. 76–95, 1983. View at Google Scholar
  6. D. S. Hull, K. Green, L. Thomas, and N. Alderman, “Hydrogen peroxide-mediated corneal endothelial damage. Induction by oxygen free radical,” Investigative Ophthalmology and Visual Science, vol. 25, no. 11, pp. 1246–1253, 1984. View at Google Scholar · View at Scopus
  7. V. Micovic, S. Golubovic, and V. Misita, “Surgical treatment of sympathetic ophthalmia,” Fortschritte der Ophthalmologie, vol. 88, no. 6, pp. 657–659, 1991. View at Google Scholar
  8. R. W. Thompson Jr., M. O. Price, P. J. Bowers, and F. W. Price Jr., “Long-term graft survival after penetrating keratoplasty,” Ophthalmology, vol. 110, no. 7, pp. 1396–1402, 2003. View at Publisher · View at Google Scholar · View at PubMed
  9. P. Y. P. Koay, H. L. Weng, and F. C. Figueiredo, “Opinions on risk factors and management of corneal graft rejection in the United Kingdom,” Cornea, vol. 24, no. 3, pp. 292–296, 2005. View at Publisher · View at Google Scholar
  10. M. G. Maguire, W. J. Stark, J. D. Gottsch et al., “Risk factors for corneal graft failure and rejection in the Collaborative Corneal Transplantation Studies,” Ophthalmology, vol. 101, no. 9, pp. 1536–1547, 1994. View at Google Scholar
  11. K. A. Williams, S. M. Muehlberg, R. F. Lewis, and D. J. Coster, “Graft survival after corneal transplantation: role of factors with the potential for recipient presensitisation,” Transplantation Proceedings, vol. 27, no. 3, pp. 2141–2142, 1995. View at Google Scholar
  12. S. R. Boyd, S. Young, and S. Lightman, “Immunopathology of the noninfectious posterior and intermediate uveitides,” Survey of Ophthalmology, vol. 46, no. 3, pp. 209–233, 2001. View at Publisher · View at Google Scholar
  13. J. De Vries, G. S. Baarsma, M. J. W. Zaal et al., “Cyclosporin in the treatment of severe chronic idiopathic uveitis,” British Journal of Ophthalmology, vol. 74, no. 6, pp. 344–349, 1990. View at Google Scholar
  14. R. B. Nussenblatt, A. G. Palestine, C. C. Chan, G. Stevens, S. D. Mellow, and S. B. Green, “Randomized, double-masked study of cyclosporine compared to prednisolone in the treatment of endogenous uveitis,” American Journal of Ophthalmology, vol. 112, no. 2, pp. 138–146, 1991. View at Google Scholar
  15. M. Ishioka, S. Ohno, S. Nakamura, K. Isobe, N. Watanabe, and Y. Ishigatsubo, “FK506 treatment of noninfectious uveitis,” American Journal of Ophthalmology, vol. 118, no. 6, pp. 723–729, 1994. View at Google Scholar
  16. C. M. L. Sloper, R. J. Powell, and H. S. Dua, “Tacrolimus (FK506) in the treatment of posterior uveitis refractory to cyclosporine,” Ophthalmology, vol. 106, no. 4, pp. 723–728, 1999. View at Google Scholar
  17. A. Joseph, D. Raj, V. Shanmuganathan, R. J. Powell, and H. S. Dua, “Tacrolimus immunosuppression in high-risk corneal grafts,” British Journal of Ophthalmology, vol. 91, no. 1, pp. 51–55, 2007. View at Publisher · View at Google Scholar · View at PubMed
  18. J. C. Hill, “Systemic cyclosporine in high-risk keratoplasty: long-term results,” Eye, vol. 9, no. 4, pp. 422–428, 1995. View at Google Scholar
  19. G. F. Cooney, J. B. Alpern, B. E. Narins, L. K. Goetz, and N. C. Cavarocchi, “Tolerance of cyclosporine oral capsules in a patient hypersensitive to standard oral and intravenous solutions of the drug,” Transplantation, vol. 49, no. 4, pp. 823–824, 1990. View at Google Scholar
  20. S. Dunn, G. Cooney, J. Sommerauer et al., “Pharmacokinetics of an oral solution of the microemulsion formulation of cyclosporine in maintenance pediatric liver transplant recipients,” Transplantation, vol. 63, no. 12, pp. 1762–1767, 1997. View at Publisher · View at Google Scholar
  21. A. Lindholm, M. Welsh, L. Rutzky, and B. D. Kahan, “The adverse impact of high cyclosporine: clearance rates on the incidences of acute rejection and graft loss,” Transplantation, vol. 55, no. 5, pp. 985–993, 1993. View at Google Scholar
  22. T. J. Schroeder, S. Hariharan, and M. R. First, “Variations in bioavailability of cyclosporine and relationship to clinical outcome in renal transplant subpopulations,” Transplantation Proceedings, vol. 27, no. 1, pp. 837–839, 1995. View at Google Scholar
  23. R. J. Ptachcinski, R. Venkataramanan, and J. T. Rosenthal, “The effect of food on cyclosporine absorption,” Transplantation, vol. 40, no. 2, pp. 174–176, 1985. View at Google Scholar
  24. A. Lindholm and J. Sawe, “Pharmacokinetics and therapeutic drug monitoring of immunosuppressants,” Therapeutic Drug Monitoring, vol. 17, no. 6, pp. 570–573, 1995. View at Google Scholar
  25. R. Venkataramanan, A. Swaminathan, T. Prasad et al., “Clinical pharmacokinetics of tacrolimus,” Clinical Pharmacokinetics, vol. 29, no. 6, pp. 404–430, 1995. View at Google Scholar
  26. R. Venkataramanan, A. Jain, V. W. Warty et al., “Pharmacokinetics of FK 506 following oral administration: a comparison of FK 506 and cyclosporine,” Transplantation Proceedings, vol. 23, no. 1, part 1, pp. 931–933, 1991. View at Google Scholar
  27. S. J. Crews, P. Mackintosh, D. R. Barry, and H. E. Willshaw, “HLA antigens and certain types of uveitis,” Transactions of the Ophthalmological Societies of the United Kingdom, vol. 99, no. 1, pp. 156–159, 1979. View at Google Scholar
  28. K. Siepmann, M. Huber, N. Stübiger, C. Deuter, and M. Zierhut, “Mycophenolate mofetil is a highly effective and safe immunosuppressive agent for the treatment of uveitis: a retrospective analysis of 106 patients,” Graefe's Archive for Clinical and Experimental Ophthalmology, vol. 244, no. 7, pp. 788–794, 2006. View at Publisher · View at Google Scholar · View at PubMed
  29. J. E. Thorne, D. A. Jabs, F. A. Qazi, D. N. Quan, J. H. Kempen, and J. P. Dunn, “Mycophenolate mofetil therapy for inflammatory eye disease,” Ophthalmology, vol. 112, no. 8, pp. 1472–1477, 2005. View at Publisher · View at Google Scholar · View at PubMed
  30. J. M. Benitez-del-Castillo, J. M. Martinez-de-la-Casa, E. Pato-Cour et al., “Long-term treatment of refractory posterior uveitis with anti-TNFα (infliximab),” Eye, vol. 19, no. 8, pp. 841–845, 2005. View at Publisher · View at Google Scholar · View at PubMed
  31. L. Niccoli, C. Nannini, M. Benucci et al., “Long-term efficacy of infliximab in refractory posterior uveitis of Behçet's disease: a 24-month follow-up study,” Rheumatology, vol. 46, no. 7, pp. 1161–1164, 2007. View at Publisher · View at Google Scholar · View at PubMed
  32. L. Sobrin, E. C. Kim, W. Christen, T. Papadaki, E. Letko, and C. S. Foster, “Infliximab therapy for the treatment of refractory ocular inflammatory disease,” Archives of Ophthalmology, vol. 125, no. 7, pp. 895–900, 2007. View at Publisher · View at Google Scholar · View at PubMed
  33. A. Pascher, J. Klupp, J. M. Langrehr, and P. Neuhaus, “Anti-TNF-alpha therapy for acute rejection in intestinal transplantation,” Transplantation Proceedings, vol. 37, no. 3, pp. 1635–1636, 2005. View at Publisher · View at Google Scholar · View at PubMed
  34. A. Pascher, C. Radke, A. Dignass et al., “Successful infliximab treatment of steroid and OKT3 refractory acute cellular rejection in two patients after intestinal transplantation,” Transplantation, vol. 76, no. 3, pp. 615–618, 2003. View at Publisher · View at Google Scholar · View at PubMed
  35. J. Pirenne and M. Kawai, “Intestinal transplantation: evolution in immunosuppression protocols,” Current Opinion in Organ Transplantation, vol. 14, no. 3, pp. 250–255, 2009. View at Publisher · View at Google Scholar · View at PubMed
  36. E. B. Suhler, J. R. Smith, M. S. Wertheim et al., “A prospective trial of infliximab therapy for refractory uveitis: preliminary safety and efficacy outcomes,” Archives of Ophthalmology, vol. 123, no. 7, pp. 903–912, 2005. View at Publisher · View at Google Scholar · View at PubMed
  37. M. A. Thiel, C. Kaufmann, D. J. Coster, and K. A. Williams, “Antibody-based immunosuppressive agents for corneal transplantation,” Eye, vol. 23, no. 10, pp. 1962–1965, 2009. View at Publisher · View at Google Scholar · View at PubMed